CDK2 and cancer: A highly specific CDK2 inhibitor is not yet commercially available, although one compound, namely PF-07104091, is under investigation in a phase I clinical study as a single agent, and in combination therapy for several cancer types, including TNBC (clinicaltrials.gov identifier: NCT04553133).